USA – MASSACHUSETTS
Vermont
New Hampshire
Massachusetts
Boston
Trends and Developments Contributed by: Patti Melick, Toby Bannon, Katherine Rubino and Kelsey Loomis Wiggin and Dana LLP Wiggin and Dana LLP is a full service law firm with more than 90 years of experience serving a diverse client base. The firm’s rapidly expanding footprint in- cludes the addition of a Boston office, which has be- come a defining force in its recent growth. Positioned within an ecosystem of leading research institutions, venture investors, emerging biotech companies, and established industry leaders, the firm is uniquely situ- ated to support clients across the USA and around the world. The Life Sciences Practice Group, led by
Connecticut
Rhode Island
Patti Melick, Toby Bannon, and Katie Rubino, brings deep industry experience supported by a multidisci- plinary team that includes Paul Hughes, Evan Kipper- man, Adam Silverman, Anthony Sabatelli, and Kelsey Loomis, among others. Their collective expertise spans global collaborations, cross border mergers, acquisitions, and licences, clinical trials, venture fi- nancings, and intellectual property strategy, litigation, and prosecution.
Authors
Patti Melick is chair of Wiggin and Dana’s life sciences practice and a leading life sciences attorney with nearly 30 years of experience advising companies in Massachusetts, across the United States, and Europe on
Katherine Rubino is based in Wiggin and Dana’s Boston office and is an IP and life sciences partner known for guiding companies through complex, high‑value transactions. A Doctor of Pharmacy and J.D., she brings rare
transformative transactions. Patti is also a Partner in the Corporate and M&A groups. Based in Boston, she counsels biotechnology, medical device, digital health, and pharmaceutical clients on cross‑border M&A, global licensing, collaborations, and strategic alliances. Patti is widely recognised for M&A and licensing.
scientific fluency to her work, enabling her to navigate the technical, regulatory, and commercial dimensions of life sciences deals. Katie advises pharmaceutical, vaccine, digital health, and medical device innovators on discovery collaborations, spin‑offs, divestitures, out‑licensing, capital raises, and M&A. Her ability to translate scientific detail into strategic legal outcomes makes her a sought‑after advisor across therapeutic modalities and emerging technologies.
Toby Bannon is a Partner in Wiggin and Dana’s Corporate Department, vice‑chair of the life sciences practice group, and co‑chair of the clinical research practice group. He advises life sciences clients on complex
Kelsey Loomis is an associate in Wiggin and Dana’s life sciences practice group, advising life sciences companies on clinical trial agreements, privacy and data protection matters, R&D
licensing, research and development collaborations, clinical trial agreements, and manufacturing, supply, and commercialisation arrangements. A lifelong science enthusiast, Toby brings a deep appreciation of each client’s technology to his advocacy and negotiations. His work has been widely recognised. Toby also brings valuable in-house experience and practicality to his practice, having previously served as R&D counsel at Alexion Pharmaceuticals.
collaborations, and complex licensing arrangements. She brings valuable in‑house perspective from her roles at Alexion Pharmaceuticals and Achillion Pharmaceuticals, where she supported global R&D teams on clinical trial operations, research programmes, and data protection matters. Her experience spans the full life cycle of product development, enabling her to deliver practical, business‑aligned guidance on emerging issues.
417 CHAMBERS.COM
Powered by FlippingBook